Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Bartoli-Abdou JK
Interpreting ‘similar outcomes’ in a small real-world comparison of apixaban and vitamin K antagonists
We read with interest the service evaluation by Bartoli-Abdou et al comparing low-dose apixaban with vitamin K antagonists (VKAs) in patients with end-stage renal disease receiving renal replacement therapy.1 The authors provide useful real-world evidence in a population for whom anticoagulation remains challenging. We suggest, however, caution in interpreting the absence of statistically significant between-group differences as ‘similar outcomes’.
Interpreting low-dose apixaban during renal replacement therapy: From anti-Xa exposure to clinical effectiveness
No abstract is available for this article. DATA AVAILABILITY STATEMENT Not applicable. This Letter contains no new or unreviewed data. REFERENCES 1, , , et al. Comparing outcomes using low-dose apixaban and anti-Xa monitoring and vitamin K antagonists in patients with renal replacement therapy. Br J Clin Pharmacol. 2026;bcp.70805. doi:10.1002/bcp.70805 2, , , et al. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Bartoli-Abdou
Contact Bartoli-Abdou, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack